title: Atrial natriuretic peptide in patients with essential hypertension. Hemodynamic, renal, and hormonal responses.
abstract: In six patients with essential hypertension (EH) and in six healthy volunteers (C) the effects of a 60-min intravenous (iv) infusion of human atrial natriuretic peptide (alpha-hANP) (24 ng/min/kg) on systemic and renal hemodynamics and renal excretory function were evaluated. Basal plasma ANP concentrations in patients with EH were higher (P less than .05) than in C (30.9 +/- 4.5 v14.0 +/- 1.7 pmol/L). Maximal effects of alpha-hANP infusion occurred after 30 to 60 min. Blood pressure (BP) declined from 154 +/- 5/109 +/- 4 to 139 +/- 7/94 +/- 4 in EH and from 117 +/- 1/72 +/- 2 to 106 +/- 1/65 +/- 3 mm Hg in C (P less than .05). Cardiac output (CO) increased transiently from 6.1 +/- 0.3 to 6.5 +/- 0.4 L/min in EH and from 6.8 +/- 0.3 to 7.2 +/- 0.5 L/min in C, whereas heart rate (HR) remained constant both in patients with EH and in C (69 +/- 3 to 72 +/- 5 and 60 +/- 3 to 63 +/- 3/min). The increases in urine flow and in urinary sodium excretion from 3.6 +/- 0.2 to 16.0 +/- 2.0 mL/min and from 230 +/- 33 to 1004 +/- 137 mumol/min, respectively, in EH were more pronounced than in C (from 3.9 +/- 1.0 to 8.4 +/- 0.8 mL/min and from 211 +/- 37 to 451 +/- 84 mumol/min); (P less than .05).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Medizinische Poliklinik, University of Bonn, Germany.
authors.forename: H G
authors.initials: HG
authors.lastname: Predel
authors.forename: O
authors.initials: O
authors.lastname: Schulte-Vels
authors.forename: K
authors.initials: K
authors.lastname: Glänzer
authors.forename: H
authors.initials: H
authors.lastname: Meyer-Lehnert
authors.forename: H J
authors.initials: HJ
authors.lastname: Kramer
mesh_terms: D000328:Adult; D000450:Aldosterone / Q000097:blood; D009320:Atrial Natriuretic Factor / Q000008:administration & dosage / Q000097:blood* / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D002302:Cardiac Output / Q000187:drug effects / Q000502:physiology; D006152:Cyclic GMP / Q000097:blood; D005919:Glomerular Filtration Rate / Q000187:drug effects / Q000502:physiology; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D006439:Hemodynamics / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000503:physiopathology; D007262:Infusions, Intravenous; D007668:Kidney / Q000098:blood supply / Q000378:metabolism / Q000503:physiopathology*; D008297:Male; D012039:Regional Blood Flow / Q000187:drug effects; D012083:Renin / Q000097:blood; D012964:Sodium / Q000652:urine; D014667:Vasopressins / Q000097:blood
chemical_list: D014667:Vasopressins; D000450:Aldosterone; D009320:Atrial Natriuretic Factor; D012964:Sodium; D012083:Renin; D006152:Cyclic GMP